文献速递新药、器械与细胞基因治疗研发基础与转化研究

AAV基因治疗Tay-Sachs病

AAV gene therapy for Tay-Sachs disease.
PubMed 文献 · Nat Med · 2022-02-10

本文报告了一项AAV基因治疗扩展准入试验,纳入两名婴儿型Tay-Sachs病(TSD)患者,以安全性为主要终点且无次要终点。两例患者分别接受鞘内或丘脑联合鞘内注射AAVrh8-HEXA与AAVrh8-HEXB,注射操作耐受良好,至今无载体相关不良事件,脑脊液HexA活性较基线升高并保持稳定;TSD-002在注射后3个月出现疾病稳定、髓鞘化持续,但治疗后6个月疾病进展明显。

要点

  • 两例婴儿型TSD患者接受AAVrh8-HEXA与AAVrh8-HEXB基因治疗,注射操作耐受良好,至今无载体相关不良事件。
  • 两例患者脑脊液HexA活性均较基线升高并保持稳定。
  • TSD-002注射后3个月疾病稳定、髓鞘化持续,但治疗后6个月疾病进展明显。

核心结论

  • 本研究提供了AAV基因治疗TSD患者的早期人体安全性和概念验证数据。

研究设计与样本

  • AAV基因治疗扩展准入试验(IND 18225),纳入两名婴儿型TSD患者,以安全性为主要终点且无次要终点。
  • 患者TSD-001在30个月时接受AAVrh8-HEXA与AAVrh8-HEXB等摩尔混合液鞘内注射,总剂量1×10^14载体基因组(vg)的75%注入小脑延髓池、25%注入胸腰段交界处。
  • 患者TSD-002在7个月时接受双侧丘脑(每侧丘脑1.5×10^12 vg)联合鞘内输注(3.9×10^13 vg)。
  • 两例患者均接受免疫抑制治疗。

主要发现

  • 注射操作耐受良好,至今无载体相关不良事件。
  • 两例患者脑脊液HexA活性均较基线升高并保持稳定。
  • TSD-002注射后3个月出现疾病稳定、髓鞘化持续,为对婴儿型TSD自然史的暂时偏离,但治疗后6个月疾病进展明显。
  • TSD-001在5岁时仍无癫痫发作,抗惊厥治疗方案与治疗前相同。
  • TSD-002在2岁时出现对抗惊厥药有反应的癫痫发作。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tay-Sachs disease (TSD) is an inherited neurological disorder caused by deficiency of hexosaminidase A (HexA). Here, we describe an adeno-associated virus (AAV) gene therapy expanded-access trial in two patients with infantile TSD (IND 18225) with safety as the primary endpoint and no secondary endpoints. Patient TSD-001 was treated at 30 months with an equimolar mix of AAVrh8-HEXA and AAVrh8-HEXB administered intrathecally (i.t.), with 75% of the total dose (1 × 1014 vector genomes (vg)) in the cisterna magna and 25% at the thoracolumbar junction. Patient TSD-002 was treated at 7 months by combined bilateral thalamic (1.5 × 1012 vg per thalamus) and i.t. infusion (3.9 × 1013 vg). Both patients were immunosuppressed. Injection procedures were well tolerated, with no vector-related adverse events (AEs) to date. Cerebrospinal fluid (CSF) HexA activity increased from baseline and remained stable in both patients. TSD-002 showed disease stabilization by 3 months after injection with ongoing myelination, a temporary deviation from the natural history of infantile TSD, but disease progression was evident at 6 months after treatment. TSD-001 remains seizure-free at 5 years of age on the same anticonvulsant therapy as before therapy. TSD-002 developed anticonvulsant-responsive seizures at 2 years of age. This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Flotte TR, Cataltepe O, Puri A, et al. AAV gene therapy for Tay-Sachs disease. Nat Med. 2022. PMID: 35145305. doi:10.1038/s41591-021-01664-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。